IRIS: a randomized controlled trial in India comparing efficacy and safety of individualized follitropin delta dosing with conventional follitropin alfa during first ovarian stimulation cycle for in vitro fertilization
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Background Women of Indian ethnicity are underrepresented among randomized controlled trials (RCTs) in reproductive medicine. We compared individualized follitropin delta with conventional follitropin alfa in infertile Indian women undergoing their first ovarian stimulation cycle for (IVF) or intracytoplasmic sperm injection (ICSI). Methods Indian participants, 21–40 years, were recruited from specialist fertility clinics across India to enroll in this assessor-blinded, multicenter bridging trial. Participants were randomly assigned (1:1) to individualized follitropin delta (algorithmic dosing based on serum anti-Müllerian hormone and bodyweight) or conventional follitropin alfa (starting dose 150 IU/day) in a GnRH antagonist protocol. The primary endpoint was the ongoing pregnancy rate per initiated cycle, and treatment difference was adjusted for age stratum (<35, 35–37 and 38–40 years) using the Mantel-Haenszel method. Secondary endpoints included ovarian responses, safety, and tolerability. An exploratory post hoc multivariate logistic analysis for ongoing pregnancy was performed using treatment group, age, AMH subgroup (<15 or ≥15 pmol) and infertility history as covariates. Findings Between 03-Dec-2021, and 13-Dec-2023, 249 participants were screened, 215 randomized, and 213 exposed to the study drug [ n = 99 follitropin delta; n = 114 follitropin alfa; modified intention-to-treat (mITT) analysis set]. Baseline characteristics were mostly similar between groups. The ongoing pregnancy rate was 22.2% (22/99) with follitropin delta vs. 14.9% (17/114) with follitropin alfa (age-adjusted difference 6.9% [95% CI −3.4–17.3]; post hoc multivariate adjusted difference 10.1%; odds ratio 1.99 [95% CI 0.95, 4.19]; p = 0.692). Participants had a mean oocyte yield ± standard deviation of 7.7 ± 5.3 in the follitropin delta group and 6.9 ± 4.2 in the follitropin alfa group. The mean total gonadotropin dose was ∼26% lower with follitropin delta (mean treatment difference −32.0 µg; p < 0.001, post-hoc analysis; mITT). The incidence of adverse events was similar between groups (34.3% vs. 29.8%), with no cases of OHSS reported. Interpretation The IRIS trial demonstrates that individualized dosing of follitropin delta is an effective and safe strategy for ovarian stimulation in Indian women while reducing total gonadotropin dose requirements. Ongoing pregnancy rates were numerically higher with follitropin delta in both the primary analysis and the post hoc multivariate logistic regression analysis, confirming the robustness of the results. Funding Ferring Pharmaceuticals A/S Registration ClinicalTrials.gov: NCT04773353; CTRI: CTRI/2021/04/032835.
Source: Frontiers in Reproductive Health
Authors: Nayana Patel(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – review & editing), Padma Rekha Jirge(Data curation, Formal analysis, Writing – review & editing), Shalini Srivastava(Data curation, Formal analysis, Writing – review & editing), Neena Malhotra(Data curation, Formal analysis, Writing – review & editing), Sanjeeva Reddy(Data curation, Formal analysis, Writing – review & editing), Vyjayanthi Srinivasan(Data curation, Formal analysis, Writing – review & editing), Mirudhubashini Govindarajan(Data curation, Formal analysis, Writing – review & editing), Manish Banker(Data curation, Formal analysis, Writing – review & editing), Enrica Gravotta(Formal analysis, Methodology, Project administration, Resources, Supervision, Writing – review & editing), Ali Falahati(Conceptualization, Data curation, Formal analysis, Methodology, Supervision, Validation, Writing – review & editing), Rita Lobo(Conceptualization, Formal analysis, Methodology, Supervision, Visualization, Writing – original draft, Writing – review & editing)
Language: English
Subfield: Reproductive Medicine
Field: Medicine
Domain: Health Sciences
Keywords: individualized dosing, follitropin delta, follitropin alfa, ovulation induction, in vitro fertilization, intracytoplasmic sperm injection, anti-Müllerian hormone, GnRH antagonist protocol, ongoing pregnancy rate, oocyte yield, ovarian response, Indian women, infertility, safety and tolerability, underrepresentation in clinical trials
Open Access status: gold
Estimated APC paid: $3,077
OpenAlex ID: W7235809647
